Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

By afschroeder • November 9, 2025

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer. Oncologist. 2025 Nov 7:oyaf371. doi: 10.1093/oncolo/oyaf371. Epub ahead of print. PMID: 41206668.

Tags: breast cancer, Endocrinology, extended-interval dosing, Hematology/Oncology, immune-related adverse events, immunotherapy, pembrolizumab, Publications

Mdivi-1 regulates mitochondrial fission and function via the CaMK2/Drp1 pathway in amyotrophic lateral sclerosis

Shai Y, Alam M, Dong X, Zhang Y, Hu Y, He Z, Feng J, Chen Y, Zhou Z, Jiang H. Mdivi-1 regulates mitochondrial fission and[...]

Carbohydrate Counting in the Real World: Mealtime Insulin Dosing Behaviors and Smartphone App Use in Adults with Type 1 Diabetes

Everett EM, Shaw E, Escobar B, Cheng D, Tiu R, Lopez R, Menjivar Cruz J, Rivas Deras A, Polan D, Wisk LE, Moin T. Carbohydrate[...]

Exposure to per-and polyfluoroalkyl substances and early-onset cancers

van Gerwen M, Monaghan M, Boni A, Florentino Puello M, Petrick LM, Leung AM. Exposure to per-and polyfluoroalkyl substances and early-onset cancers. Carcinogenesis. 2026 Jul[...]